TD Cowen Lowers Surgery Partners (NASDAQ:SGRY) Price Target to $20.00

Surgery Partners (NASDAQ:SGRY) had its target price reduced by investment analysts at TD Cowen from $28.00 to $20.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price indicates a potential upside of 42.86% from the company’s previous close.

SGRY has been the subject of several other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a research report on Wednesday. Mizuho reduced their price objective on Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday. Barclays lowered their target price on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Royal Bank Of Canada reduced their price target on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, UBS Group decreased their price target on Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Surgery Partners currently has an average rating of “Moderate Buy” and an average target price of $24.45.

Surgery Partners Stock Performance

Shares of Surgery Partners stock traded down $0.08 on Thursday, reaching $14.00. 911,582 shares of the company were exchanged, compared to its average volume of 1,697,499. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -22.58 and a beta of 1.95. Surgery Partners has a 1-year low of $12.25 and a 1-year high of $24.64. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.72 and a current ratio of 1.87. The company’s 50-day moving average is $15.28 and its two-hundred day moving average is $18.24.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The company had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same period in the prior year, the business earned $0.44 earnings per share. Surgery Partners’s quarterly revenue was up 2.4% on a year-over-year basis. As a group, research analysts expect that Surgery Partners will post 0.67 earnings per share for the current fiscal year.

Surgery Partners announced that its Board of Directors has authorized a stock buyback plan on Thursday, February 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to reacquire up to 9.7% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Alpine Global Management LLC acquired a new position in shares of Surgery Partners in the 4th quarter worth approximately $175,000. Empowered Funds LLC boosted its holdings in Surgery Partners by 1,340.9% during the fourth quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock worth $2,494,000 after buying an additional 150,216 shares in the last quarter. One68 Global Capital LLC acquired a new position in Surgery Partners in the fourth quarter worth approximately $371,000. Man Group plc bought a new position in shares of Surgery Partners in the fourth quarter valued at $5,080,000. Finally, Inspire Investing LLC lifted its position in shares of Surgery Partners by 45.4% during the 4th quarter. Inspire Investing LLC now owns 30,073 shares of the company’s stock valued at $465,000 after acquiring an additional 9,384 shares during the last quarter.

More Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Board authorizes $200M share repurchase (up to ~9.7% of shares), signaling management believes the stock is undervalued and providing buy-side support. RTT News: Buyback
• Positive Sentiment: Surgery Partners completed the acquisition of Preferred Vascular Group (8 ASCs focused on dialysis access), expanding its ASC footprint and specialized service mix. Strategic M&A can support growth and revenue diversification. PR Newswire: PVG Acquisition
• Positive Sentiment: UBS kept a “buy” rating despite cutting its price target from $29 to $21 — the new target still implies substantial upside from current levels, which may attract value-seeking investors. Benzinga: UBS PT Cut
• Neutral Sentiment: Mizuho trimmed its target from $19 to $17 and maintained an “outperform” rating, reducing upside but not turning bearish. Benzinga: Mizuho PT Cut
• Neutral Sentiment: Coverage and transcripts of the Q4 2025 earnings call highlight revenue growth but emphasize margin pressure and an EPS miss — mixed operational signals that leave valuation judgments split. Yahoo Finance: Q4 Highlights
• Negative Sentiment: Barclays lowered its price target to $14, close to current trading levels, reducing upside expectations from that broker and increasing near-term downside risk. American Banking News: Barclays PT Cut
• Negative Sentiment: Multiple outlets report SGRY hit a 52-week low after the earnings release; this technical weakness can prompt further selling and deter short-term buyers. MSN: 52-Week Low
• Negative Sentiment: Johnson Fistel announced an investor investigation into potential claims against Surgery Partners’ executives, adding legal/settlement risk and likely increasing investor caution. GlobeNewswire: Investor Investigation

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.